Existing biomarkers: Their importance in identifying disease progression and guiding treatment decisions
In the first part of the third CONy & Teva Neuroscience MS Matters webinar, Prof. Sven Schippling, University Hospital Zürich, Switzerland, and Dr Jens Kuhle, University of Basel, Switzerland, highlight the broad range of uses of current biomarkers, as well as the difficulties associated with their validation.
Video zinc code: HQ/MS/19/0015
Unmet need for novel biomarkers in MS – Could they provide the answers to key questions?
Following on their discussion, Prof. Schippling and Dr Kuhle address what questions they hope novel biomarkers will answer in the future, and how comparability and standardisation issues are some of the main factors hindering advances in this area.
What could potential new biomarkers in MS mean for patients?
In the concluding section of the webinar, Prof. Schippling and Dr Kuhle focus on optical coherence tomography (OCT) biomarkers and neurofilament light chain (NFL). They highlight the need for longitudinal studies that use the gold standard measures of disease activity in order to validate these measures.
Prof. Sven Schippling University Hospital Zürich, Switzerland
Dr Jens Kuhle University of Basel, Switzerland
Co-presenter Jens Kuhle was recently appointed as Head of the newly founded Multiple Sclerosis Centre at the University Hospital Basel, Switzerland. He is also Principal Investigator for the Swiss MS Cohort Study, a national academic network dedicated to biomarker and outcome research in MS. Dr Kuhle obtained his MD from the Eberhard-Karls University in Tübingen, Germany and specialised in neurology and neuroimmunology at the University Hospital Basel. He is the main coordinator of an international consortium for the validation of neurofilaments as clinical biomarkers in MS. Dr Kuhle acts as a reviewer for the Swiss, UK and American Multiple Sclerosis societies along with multiple MS-related journals. His research activities focus on biofluid markers related to the course and outcome of neurological diseases in general, and specifically on establishing neurofilament light chains as the first blood-based biomarker in MS. Based on this research, he received his PhD in Neuroimmunology at Queen Mary University, London, UK in 2014. This webinar is organised and funded by Teva Pharmaceuticals(Teva Pharmaceuticals Europe BV, Piet Heinkade 107, 1019 GM Amsterdam, The Netherlands)